相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naive patients from the French National Health Insurance database (SNIIRAM)
E. Sbidian et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Drug survival of biologic treatments in psoriasis: a systematic review
Daniel J. No et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Cost-of-illness of psoriasis - results of a German cross-sectional study
D. Jungen et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
A. Egeberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Differential Drug Survival of Second-line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Ireny Y. K. Iskandar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Biologicals and small molecules in psoriasis: A systematic review of economic evaluations
Christian Kromer et al.
PLOS ONE (2018)
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Pei-Tzu Lin et al.
SCIENTIFIC REPORTS (2018)
Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database
Rosarin Sruamsiri et al.
BMC DERMATOLOGY (2018)
Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents
Joerg Mahlich et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
I. Y. K. Iskandar et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients
Benjamin Chastek et al.
ADVANCES IN THERAPY (2016)
Quality of psoriasis care in Germany: results of the national health care study PsoHealth3
Anna Langenbruch et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2016)
The German National Program on Psoriasis Health Care 2005-2015: results and experiences
M. Augustin et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2016)
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry
J. Zweegers et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Drug survival rates and reasons for drug discontinuation in psoriasis
Tobias Arnold et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2016)
Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population
Jalpa A. Doshi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
A. Menter et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
Joerg Mahlich et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B. Warren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies
J. -M. Carrascosa et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
Sarah Neubauer et al.
HEALTH ECONOMICS REVIEW (2014)
Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment
Robert L. Boggs et al.
BMC DERMATOLOGY (2014)
Drug survival rates in patients with psoriasis after treatment with biologics
Yoshinori Umezawa et al.
JOURNAL OF DERMATOLOGY (2013)
Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data
Soo-Kyung Cho et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany
Matthias Augustin et al.
ACTA DERMATO-VENEREOLOGICA (2010)
Disease severity, quality of life and health care in plaque-type psoriasis: A multicenter cross-sectional study in Germany
M. Augustin et al.
DERMATOLOGY (2008)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
Quality of life in patients with psoriasis
Monali J. Bhosle et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2006)
Persons insured with the German Statutory Sickness Funds or privately insured: Differences in health and health behaviour
P. Kriwy et al.
GESUNDHEITSWESEN (2006)
分享论文
